Article published in an international scientific journal
Cereno Scientific AB has published its article "A First in Class Treatment for Thrombosis Prevention. A Phase I Study With CS1, a New Controlled Release Formulation of Sodium Valproate” in the Journal of Cardiology and Vascular Medicine. The article is based on Cereno's first clinical study with its drug candidate CS1, which was concluded last year with positive results regarding safety, pharmacokinetic properties and effect on biomarker (PAI-1). The publication also strengthens the company's exposure within the thrombosis prevention field.
– I am pleased that our article has been published in the Journal of Cardiology and Vascular Medicine. The approval is an acknowledgment that our research is of high quality and that we continue to generate international interest, says Cereno Scientific's CEO Sten R. Sörensen.
The article is based on Cereno's research within the field of thrombosis prevention and the company's first clinical study on the drug candidate CS1. The main author of the article is the company's co-founder Niklas Bergh, who is an associate professor of experimental cardiology at the Sahlgrenska Academy, University of Gothenburg.
Cereno Scientific's primary focus is now to prepare CS1 for a clinical Phase II study in Russia and Bulgaria, with the hope to receive a study approval in the second half of 2019.
For further information, please contact:
Daniel Brodén – CFO
Tel: +46 768 66 77 87
About Cereno Scientific AB
Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.